-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in Hong Kong stocks | Goli Pharmaceutical-B (01672) rose more than 5%, ASC30_48 FDC and other pre-clinical studies unveiled at ObesityWeek

Zhitongcaijing·11/17/2026 06:25:04
Listen to the news

The Zhitong Finance App learned that Goli Pharmaceutical-B (01672) rose by more than 5%. As of press release, it had risen 5.26% to HK$4.5, with a turnover of HK$4.193,800.

According to the news, Collie Pharmaceutical-B announced that Clarion recently showcased the oral small molecule GIPR agonist ASC48, GLP-1R/GIPR dual-target oral small molecule ASC30_48 FDC (fixed dose compound formulation of ASC30 and ASC48), and long-term injections of GLP-1R/GIPR/GCGR three-target agonist polypeptide ASC37 at ObesityWeek® 2026 held in Washington, D.C., from November 14 to 17, 2026 Key preclinical findings.

ASC30_48 FDC is an oral small molecule compound developed independently by Goli. It targets GLP-1R and GIPR, and is expected to be the first first-in-class (first-in-class) oral treatment for obesity and other metabolic diseases, once a day, one tablet at a time. Furthermore, according to preliminary preclinical data, ASC37 has shown good curative effects in weight loss and appetite suppression, and has good pharmacokinetic properties, supporting that it can be expected to become the best-in-class (best-in-class) treatment candidate.